Breakthrough software innovation delivers improved clinical capabilities, personalization, lower costs and operational results
CHICAGO -- December 3, 2013 -- Today at the 2013 Radiological Society of North America (RSNA) annual meeting, GE Healthcare, a unit of General Electric Company (NYSE: GE), unveiled four software breakthroughs to deliver improved clinical capabilities, productivity and diagnostic confidence for clinicians.
CHICAGO -- December 2, 2013 -- GE Healthcare, a unit of General Electric Company (NYSE: GE), is dedicated to providing clinicians worldwide with leading radiation dose management innovations. X-ray dose is a critical issue and GE Healthcare has collaborated with top institutions to develop strategies to better manage it. At this year's 2013 Radiological Society of North America (#RSNA13) annual meeting, GE Healthcare is showcasing several new offerings to enable low-dose imaging procedures and help clinicians track and measure dose.
CHICAGO -- DECEMBER 2, 2013 -- GE Healthcare, a unit of General Electric Company (NYSE: GE), today announced at the Radiological Society of North America's 99th Scientific Assembly and Annual Meeting in Chicago, Illinois that its 510(k)-pending Revolution CT^ has captured a motion free image of the human heart in just one beat.
South Australian healthcare providers and patients will benefit from improved access to treatment, better education, and advanced research as part of a world-leading 5 year partnership announced today between GE Healthcare, SA Health and the South Australian Medical Research Institute (SAHMRI) .
As part of this agreement South Australia's first Cyclotron™ is currently being installed and will be operated out of the new world class health and biomedical precinct that includes SAHMRI, the Royal Adelaide Hospital and the University of South Australia.
CHALFONT ST. GILES, UK -- 19 November 2013 -- GE Healthcare Life Sciences, (NYSE: GE) and Cellectis Group (Alternext: ALCLS), the global genome engineering specialist, announced today that GE Healthcare has licenced Cellectis to develop, manufacture and sell models derived from stem cells for use in drug discovery and toxicity screening.
GE's high-performance LEAPmbr* membrane bioreactor (MBR) wastewater-treatment technology will be the centerpiece of an upgrade to Unitywater's Maleny sewage treatment plant in Queensland and is expected to allow the plant to double the amount of water treated per day to one million litres.
